GlassScriptPhysician profile
Martin Fejka
NPI 1578521233
$2,791.20
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,799 · 2020: $162 · 2021: $266 · 2022: $273 · 2023: $82.08 · 2024: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $291.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $1,301.94 | 2019-2024 | (Az7) Lasers |
| Abbott Laboratories | $294.74 | 2019-2024 | Perclose Proglide |
| Pfizer INC. | $250.74 | 2019-2024 | |
| Boston Scientific Corporation | $246.36 | 2019-2024 | Watchman Flx |
| Medtronic Vascular, INC. | $227.13 | 2019 | |
| Abiomed | $181.56 | 2019 | |
| Amgen INC. | $74.05 | 2019-2024 | Repatha |
| Asahi Intecc USA, INC. | $38.25 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $37.55 | 2019-2024 | Camzyos |
| Cardiovascular Systems INC. | $32.70 | 2019 | |
| Angiodynamics, INC. | $24.16 | 2024 | Angiovac |
| Biotronik INC. | $20.23 | 2021 | |
| Medtronic, INC. | $17.79 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.97 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.59 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $13.44 | 2024 | Zilver Ptx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Fejka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.